INNOVATE CORP. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
INNOVATE CORP. (VATE) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2022-03-09
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2021-12-31 was $0.00.
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2021-09-30 was $0.00.
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2020 was $72.50M, a 705.56% increase from fiscal 2019.
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2019 was $9.00M.
- INNOVATE CORP. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2017 was $5.10M, a 104.00% increase from fiscal 2016.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month as first filed | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month as first filed | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month as first filed | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $0.00 derived: sum of 2 quarters · filed 2022-03-09 | $0.00 10-K · filed 2022-03-09 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $0.00 derived: sum of 2 quarters · filed 2022-03-09 | $90.80M derived: sum of 3 quarters · filed 2022-03-09 | $72.50M 10-K · filed 2022-03-09 | $63.40M 10-K · filed 2021-03-10 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $90.80M derived: sum of 2 quarters · filed 2021-11-04 | $72.50M 10-Q · filed 2021-11-04 | $58.70M 10-Q · filed 2020-11-09 | $72.80M derived: sum of 4 quarters · filed 2021-11-04 | |||
| 2020-06-30 | $90.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $72.50M 10-Q · filed 2021-08-06 | $53.80M 10-Q · filed 2020-08-10 | $72.80M derived: sum of 3 quarters · filed 2021-08-06 | $78.00M derived: sum of 4 quarters · filed 2021-08-06 | |||
| 2020-03-31 | -$18.30M 10-Q · filed 2020-05-11 | -$18.00M derived: sum of 2 quarters · filed 2021-03-10 | -$12.80M derived: sum of 3 quarters · filed 2021-03-10 | -$15.10M derived: sum of 4 quarters · filed 2021-03-10 | ||||
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $5.50M derived: sum of 2 quarters · filed 2021-03-10 | $3.20M derived: sum of 3 quarters · filed 2021-03-10 | $9.00M 10-K · filed 2021-03-10 | ||||
| 2019-09-30 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.90M derived: sum of 2 quarters · filed 2020-11-09 | $8.70M 10-Q · filed 2020-11-09 | -$11.60M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | -$2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $3.50M 10-Q · filed 2020-08-10 | -$16.80M derived: sum of 3 quarters · filed 2020-10-07 | $29.30M derived: sum of 4 quarters · filed 2020-10-07 | ||||
| 2019-03-31 | $5.80M 10-Q · filed 2020-05-11 | -$14.50M derived: sum of 2 quarters · filed 2020-10-07 | $31.60M derived: sum of 3 quarters · filed 2020-10-07 | $34.10M derived: sum of 4 quarters · filed 2020-10-07 | ||||
| 2018-12-31 | -$20.30M derived: 8-K 12 month − 10-Q 9 month · filed 2020-10-07 | $25.80M derived: sum of 2 quarters · filed 2020-10-07 | $28.30M derived: sum of 3 quarters · filed 2020-10-07 | $28.80M 8-K · filed 2020-10-07 | ||||
| 2018-09-30 | $46.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $48.60M derived: sum of 2 quarters · filed 2019-11-05 | $49.10M 10-Q · filed 2019-11-05 | $49.13M 10-Q · filed 2018-11-06 | $51.32M derived: sum of 4 quarters · filed 2019-11-05 | |||
| 2018-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $3.00M 10-Q · filed 2019-08-08 | $2.99M 10-Q · filed 2018-08-08 | $5.22M derived: sum of 3 quarters · filed 2019-08-08 | $6.20M derived: sum of 4 quarters · filed 2019-08-08 | |||
| 2018-03-31 | $500.00K 10-Q · filed 2019-05-07 | $497.00K 10-Q · filed 2018-05-10 | $2.72M derived: sum of 2 quarters · filed 2019-05-07 | $3.70M derived: sum of 3 quarters · filed 2019-05-07 | $5.23M derived: sum of 4 quarters · filed 2019-05-07 | |||
| 2017-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $3.20M derived: sum of 2 quarters · filed 2019-03-12 | $4.73M derived: sum of 3 quarters · filed 2019-03-12 | $5.10M 10-K · filed 2019-03-12 | $5.15M 10-K · filed 2018-03-14 | |||
| 2017-09-30 | $985.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.51M derived: sum of 2 quarters · filed 2018-11-06 | $2.88M 10-Q · filed 2018-11-06 | $7.90M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $1.90M 10-Q · filed 2018-08-08 | $6.92M derived: sum of 3 quarters · filed 2019-03-12 | $5.49M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-03-31 | $368.00K 10-Q · filed 2018-05-10 | $5.39M derived: sum of 2 quarters · filed 2019-03-12 | $3.96M derived: sum of 3 quarters · filed 2019-03-12 | $5.93M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2016-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $3.59M derived: sum of 2 quarters · filed 2019-03-12 | $5.57M derived: sum of 3 quarters · filed 2019-03-12 | $2.50M 10-K · filed 2019-03-12 | $2.53M 10-K · filed 2017-03-09 | |||
| 2016-09-30 | -$1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $548.00K derived: sum of 2 quarters · filed 2017-11-08 | -$2.52M 10-Q · filed 2017-11-08 | |||||
| 2016-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$1.09M 10-Q · filed 2017-08-09 | ||||||
| 2016-03-31 | -$3.07M 10-Q · filed 2017-05-10 | |||||||
| 2015-12-31 | -$6.05M 10-K · filed 2018-03-14 | -$3.17M 10-K · filed 2016-03-15 | ||||||
| 2014-12-31 | -$1.17M 10-K · filed 2017-03-09 | -$1.61M 10-K · filed 2015-03-16 | ||||||
| 2013-12-31 | $0.00 10-K/A · filed 2016-03-15 | |||||||
| 2012-12-31 | $0.00 10-K/A · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TECHPRECISION CORP (TPCS) | United States | $0.053B | 108.37 |
| Proto Labs Inc (PRLB) | United States | $2.226B | 64.02 |
| Arcosa, Inc. (ACA) | United States | $7.195B | 14.51 |
| VALMONT INDUSTRIES INC (VMI) | United States | $8.988B | 22.19 |